Susan Rosencrance

home / authors / susan-rosencrance

Susan Rosencrance, PhD is with the Center for Drug Evaluation and Research, FDA

Articles

Common Deficiencies in ANDAs for Dermatologic Drug Products

Common Deficiencies in ANDAs for Dermatologic Drug Products

Rong-Kun Chang;Susan Rosencrance;Andre Raw;Bing Cai, PhD;
September 2nd 2016

Companies may potentially accelerate the approval of generic drugs by avoiding deficiencies in ANDA submissions.

Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry

Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry

Geoffrey Wu;Lane Christensen;Thomas O’Connor;Frank Holcombe Jr.;Susan Rosencrance;Andre Raw;Kristina Adams;Xiaochuan Yang;Min Li
September 1st 2015

An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.

Latest Updated Articles

Buy, Sell, Hold: Cell and Gene Therapy
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Challenges and Triumphs in Next-Generation Biotherapeutic Development
Published: November 20th 2024 | Updated: December 3rd 2024
Challenges and Triumphs in Next-Generation Biotherapeutic Development
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
Published: November 23rd 2024 | Updated: December 3rd 2024
FDA Grants Approval to Kedrion to Produce PLGD-1 Therapeutic at Bolognana Plant
AAPS PharmSci 360: Challenges in Peptide-Based Drugs
Published: November 12th 2024 | Updated: December 3rd 2024
AAPS PharmSci 360: Challenges in Peptide-Based Drugs
Published: November 13th 2024 | Updated: December 3rd 2024
Risk-Based Development Supporting Process Qualification for Spray-Dried Dispersion